Hyundai Pharm (004310) — Cash Flow Reinvestment Rate

Latest as of May 2026: 5.06x

Hyundai Pharm (004310) has a Cash Flow Reinvestment Rate of 5.06x as of May 2026, reinvesting ₩12.10 Billion (capex ₩1.09 Billion plus investments ₩-11.01 Billion) from operating cash flow of ₩2.39 Billion. See Hyundai Pharm (004310) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

5.06x
(Capex + Investments) / Operating CF

Total Reinvested

₩12.10 Billion
Capex + Investments

Operating Cash Flow

₩2.39 Billion
KRW

Capital Expenditures

₩1.09 Billion
KRW

Hyundai Pharm Cash Flow Reinvestment Rate (2010–2022)

Historical reinvestment intensity for Hyundai Pharm across 8 annual periods. For the full cash flow conversion analysis, see 004310 cash flow metrics.

Annual Cash Flow Reinvestment Rate for Hyundai Pharm (2010–2022)

Year-by-year capital reinvestment analysis for Hyundai Pharm. See Hyundai Pharm (004310) financial flexibility to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (KRW) Operating CF Capex YoY Change
2022 1.43x ₩16.57 Billion ₩11.62 Billion ₩6.58 Billion ▲ +7.0%
2021 1.33x ₩6.84 Billion ₩5.13 Billion ₩6.81 Billion ▼ -23.4%
2020 1.74x ₩18.79 Billion ₩10.80 Billion ₩6.40 Billion ▲ +138.0%
2019 0.73x ₩5.09 Billion ₩6.96 Billion ₩2.36 Billion ▼ -74.6%
2018 2.87x ₩8.14 Billion ₩2.83 Billion ₩2.67 Billion ▲ +727.5%
2013 0.35x ₩2.76 Billion ₩7.95 Billion ₩2.24 Billion ▼ -45.2%
2011 0.63x ₩3.97 Billion ₩6.27 Billion ₩3.68 Billion ▼ -58.9%
2010 1.54x ₩4.13 Billion ₩2.68 Billion ₩3.95 Billion
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow